TerminatedNCT00183612
Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents
Medication studyAges 6–18United StatesBipolarity
Understand this study
Who could participate?
Listed age limits: 6 years to 18 years.
- Listed locations
- Belmont and 1 more locationSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateMay 2000
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 68
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Locations
- United States
- Age range
- From 6 Years to 18 Years
- Official registry ID
- NCT00183612
- Official title
Show the full official title
Developmental Pharmacokinetics of Psychotropic Drugs: Olanzapine
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Belmont · Medford
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Olanzapine.
Who can participate?
Listed age limits: 6 years to 18 years.
Is this study still recruiting?
The registry lists this study as terminated.
